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Abstract
To identify determinants of respiratory disease progression in late-onset Pompe disease (LOPD), we studied relationships between pulmonary
function, respiratory muscle strength, gas exchange, and respiratory control. Longitudinal evaluation of 22 LOPD patients (mean age 38 years) was
performed at 6-month intervals for 6–24 months. Measurements included vital capacity (VC), maximum inspiratory pressure (MIP), maximum
expiratory pressure (MEP), tidal volume (VT), dead space (VD), and ventilatory response to CO2. Although reduction in VC correlated with MIP
and MEP (p < 0.0001), some patients had normal VC despite reduced MIP and MEP (5 [23%] and 9 [41%] patients, respectively). Daytime
hypercapnia was associated with reduced VC (<60% predicted) and MIP (<40% predicted). Moreover, chronic hypercapnia was associated with
elevated VD/VT (≥0.44) due to falling VT (≈300 ml), compatible with reduced efficiency of CO2 clearance. The presence of hypercapnia and/or
ventilatory support was associated with reduced ventilatory responsiveness to CO2 (≤0.7 l/min/mmHg). We conclude that daytime hypercapnia, an
indicator of chronic respiratory failure, is tightly linked to the degree of respiratory muscle weakness and severity of pulmonary dysfunction in
LOPD patients. Reductions in CO2 clearance efficiency and ventilatory responsiveness may contribute to the development of chronic daytime
hypercapnia.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Keywords: Late-onset Pompe disease; Respiratory failure; Vital capacity; Maximum inspiratory pressure; Hypercapnia; Respiratory control
1. Introduction
Late-onset Pompe disease (LOPD) is a rare autosomal
recessive neuromuscular disorder caused by lysosomal
α-glucosidase acid (GAA) deficiency [1]. GAA deficiency
induces a progressive glycogen accumulation (especially in
skeletal muscles) that leads to severe proximal and respiratory
muscle dysfunction [2]. Pulmonary dysfunction is prominent in
LOPD, with 79% of adults and 59% of children having some
degree of respiratory insufficiency [2,3] that eventually
progresses to respiratory failure [4].
The etiology of pulmonary dysfunction in LOPD patients is
related to weakness of the diaphragm and accessory muscles of
respiration [2]. Physiologic evaluation reveals restrictive
dysfunction that manifests as reduction in vital capacity (VC),
maximal inspiratory pressure (MIP), and maximal expiratory
pressure (MEP) [2,5]. Over time, the progressive weakening
of respiratory muscles is associated with development of
respiratory failure and alveolar hypoventilation, which can be
identified by daytime hypercapnia on blood gas evaluation [6].
The development of respiratory failure necessitates initiation of
ventilatory support (nocturnal and daytime ventilation), which
is associated with reduced quality of life. Moreover, respiratory
failure is the most frequent cause of death in LOPD patients
[7–10].
Despite numerous studies revealing progressive restrictive
respiratory disease in patients [3,4,11–13], the determinants of
progression from respiratory dysfunction to failure in LOPD
have not been reported. Studies have shown an association
between levels of respiratory impairment (reduction in VC
and/or inspiratory pressure), development of sleep-disordered
breathing, and the presence of respiratory failure [7,14–17].
However, the interrelationship between mechanical limitation
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of lung function, abnormalities in gas exchange, and measures
of respiratory control has not been investigated in LOPD. Thus,
we evaluated disease course, symptoms, respiratory function,
and daytime hypercapnia in a cohort of 22 LOPD patients that
were not receiving therapy. Our goal was to evaluate the
evolution of respiratory function over time and study the
relationships between measures of pulmonary function,
respiratory muscle strength, gas exchange, and respiratory
control to identify determinants of disease progression from
respiratory dysfunction to failure. To accomplish these goals,
data were reviewed from a cohort of patients studied prior to
development of enzyme replacement therapy.
2. Methods
2.1. Study design
This was a 24-month observational study conducted in a
cohort of untreated patients with LOPD that were studied from
1996 to 1999 at Bellevue Hospital, NewYork University School
of Medicine, New York. After signing informed consent forms,
patients completed a baseline evaluation. Longitudinal
evaluation was performed at 6-month intervals for a maximum
of 24 months. Diagnosis of Pompe disease was confirmed in all
patients by a combination of endogenous GAA activity (either
from leukocytes or cultured fibroblasts) and muscle biopsy.
2.2. Participants
Eligible patients had documented GAA enzyme deficiency
(<75% of the lower limit of the normal adult range) or GAA
gene mutation(s) in the medical record and were aged ≥18 years
at the time of enrollment. Patients were excluded if they had
previously received any experimental or approved therapy for
Pompe disease or if they had a medical condition that, in the
opinion of investigators, might compromise the subject’s ability
to comply with study protocol requirements.
2.3. Data collection
Patient data were collected on the following: 1)
demographics; 2) presence of congenital abnormalities; 3)
family history of Pompe disease; 4) data from respiratory
assessments; 5) documented treatments and surgeries,
including use of ventilatory assistance either during sleep or
continuously throughout the day; 6) ability to ambulate and use
of assistive devices; and 7) clinical laboratory data (creatine
phosphokinase, thyroid function, arterial blood gas). Data were
collected by the investigators, who transcribed medical records
onto case report forms. There was no overlap between this
patient cohort and previous literature reports.
2.4. Measurements
2.4.1. Pulmonary function and respiratory muscle strength
Pulmonary function testing was conducted with patients in
the upright position using a spirometer and a plethysmograph
(P.K. Morgan, Haverhill, MA, USA) to assess VC, inspiratory
capacity (IC), and functional residual capacity. Respiratory
muscle strength was evaluated by measuring MIP and MEP
using a manometer (Physiodyne Inc, Quogue, NY, USA).
Pressure was recorded in cmH2O. The testing equipment was
constant in all subjects at all assessments. The percentage of
predicted normal values were calculated using published
equations [18,19].
For the 2 patients with a tracheostomy tube, testing was
performed after the tube was removed and the stoma was
covered with an air tight dressing. This technique allowed for
assessment of respiratory function without the confounding
upper airway obstruction that would be present with the
tracheostomy tube in place.
2.4.2. Resting ventilation and blood gas tensions
Resting ventilation was assessed in all patients to determine
the resting respiratory pattern, effective dead space, and
alveolar ventilation. Patients were studied in the upright
position while breathing at their resting level for 20 minutes.
The exhaled air was collected in a 120 liter spirometer (Tissot
gasometer, W.E. Collins, Inc., Braintree, MA, USA).
Measurements of respiratory rate and tidal volume (VT) were
obtained using the spirometer, while exhaled CO2 and oxygen
concentrations were determined using a metabolic cart (Fitco
Max-1, Physiodyne, Farmingdale, NY, USA). Data were
analyzed after stabilization of the ventilatory rate and pattern
(final 3 to 5 minutes of the study). Patients were included in the
final analysis only if steady state conditions were verifiable
(n = 17) based on normal values for resting metabolic rate
(oxygen consumption, CO2 production, and respiratory
quotient). The dead space volume (VD) and dead space to tidal
volume ratio (VD/VT) were calculated using standard equations
[20]. Arterial blood was collected for analysis of PaCO2 at the
end of the study.
2.4.3. Respiratory control
The ventilatory response to CO2 was assessed in all patients
by a rebreathing technique [21]. Ventilation was measured as
the subject rebreathed from a closed system containing
increased CO2 in a hyperoxic gas mixture. The partial pressure
of carbon dioxide (PCO2) was monitored by end-tidal level and
was allowed to rise above the initial mixed venous level over 4
minutes. Automated custom software was utilized to perform
this test and to acquire the ventilatory and gas signals. The
ventilatory response to CO2 was assessed as the slope of the
relationship between minute ventilation and PCO2. Valid data
were obtainable in 20 patients.
2.5. Data analysis
Data are summarized as prevalence, mean, and standard
deviation and/or range. Analysis of the relationship between
inspiratory pressure to lung volume was performed using
logarithmic regression, as previously described [16,22]. This
approach accounts for the nonlinear relationship characteristic
of normal subjects. The relationship between expiratory
pressure and VC was assessed by linear regression. All analyses
were conducted with either Microsoft Excel for Windows
(v2010) or SigmaPlot for Windows (v12.0).
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3. Results
3.1. Demographics and baseline characteristics
The demographic and baseline characteristics of patients are
shown in Table 1. Mean age ± standard deviation (SD) was
38.0 ± 13 years (range, 19–60), and mean duration of disease
was 10.2 ± 8.4 years (range, 1–30). Walking aids were used by
6 patients, and ventilatory support was used by 7 patients. At
baseline, mean VC ± SD in the sitting position was 69 ± 27%
predicted. Of the 22 patients, 10 (45%) had VC values in the
normal range (>80% predicted). The remaining 12 patients
(55%) had VC values <80%, indicating restrictive respiratory
disease varying from mild to severe by American Thoracic
Society standards. Clinical history did not reveal an explanation
for the restrictive dysfunction other than neuromuscular
weakness in any subject, and chest radiographs (n = 16) were
either normal or revealed atelectasis and/or focal
postinflammatory fibrotic changes. One subject had previously
undergone surgery for scoliosis. Elevated PaCO2 was noted in 5
patients; the serum bicarbonate concentration was elevated in
all 5 patients (>31 mEq/l), indicating the presence of renal
compensation and confirming persistence of the hypercapnic
state. The arterial partial pressure of oxygen was reduced in the
subjects with hypercapnia. However, calculation of the
alveolar-arterial oxygen pressure difference revealed normal
values in all patients, indicating that gas transfer across the
alveolar air interface was within normal limits.
The top panel of Fig. 1 illustrates longitudinal VC data for
the study cohort. Data were available for 18 of the 22 patients,
and time points ranged from 6 to 24 months. VC, expressed as
% predicted, was essentially stable and varied within 5% of
baseline in 11 (61%) of the patients. A decline in VC >5% was
seen in 3 (17%) patients. An increase >5% was seen in 4 (22%)
patients; in 3 of these 4 patients, the increase in VC was not
attributable to an increase in diaphragm strength since MIP and
IC remained constant at all time points. In many cases, the
longitudinal trend was not consistent and test-to-test variability
was noted.
The bottom panel of Fig. 1 shows longitudinal MIP data for
the study cohort. In contrast to the variable course of VC, the
measured MIP remained essentially stable in the majority of
subjects. Only 3 individuals demonstrated changes ≥10 cmH2O.
3.2. Relationship between lung volumes and respiratory
muscle strength
Fig. 2 illustrates the relationships between lung volume (VC
and IC) and inspiratory muscle strength (MIP) in LOPD
patients. The top panel plots VC as a function of the MIP;
analysis of the data revealed a significant correlation (r2 = 0.71,
p < 0.0001). Although the observed data were similar to the
predicted relationship (dotted line), the data were shifted
downward (solid line), indicating that for any degree of
inspiratory muscle weakness there was a disproportionate
reduction in VC. These results suggest a decrease in either lung
and/or chest wall compliance in patients with LOPD. Of note, 5
patients demonstrated normal VC (>80% predicted) despite
reduction in MIP to values <80% predicted. The patients
receiving ventilatory support (open symbols) demonstrated the
most severe impairment in respiratory function; VC and MIP
values were consistently below 60% and 40% predicted,
respectively. The bottom panel illustrates similar data for IC,
highlighting a respiratory restriction characterized by the
inability to distend the lungs and chest cage (r2 = 0.63,
p < 0.0001).
The relationship between VC and MEP (a measure of
expiratory muscle strength) is shown in Fig. 3. MEP was
abnormal in all patients varying from borderline low to severely
decreased values (range, 10–75% predicted). A linear
Table 1
Demographics and baseline characteristics of the
patient population.
Characteristic Data*
Number of patients enrolled, N 22
Age at enrollment, yrs
Mean 38 ± 13
Range 19–60
Sex, n
Male 9
Female 13
BMI†
Mean 23.5 ± 4.8
n (%)
<20 6 (32)
20–25 5 (26)
25–30 6 (32)
>30 2 (11)
Duration of disease, yrs
Mean 10.2 ± 8.4
Range 1–30
Age of disease onset, yrs
Mean 29 ± 13
Range 11–57
CPK (IU/L)
Mean 645 ± 529
Walking aids‡, n (%)
None 15 (68)
Cane/walker 2 (10)
Wheelchair 4 (19)
Ventilatory support, n (%)
None 15 (68)
NIV 5 (23)
Tracheostomy 2 (9)
VC (% predicted)
Mean 69 ± 27
n (%)
>80 10 (45)
60–80 5 (23)
40–60 3 (14)
<40 4 (18)
PaCO2 (mmHg)
Mean 42 ± 11
n (%)
<45 17 (77)
≥45 5 (23)
* Plus–minus values are mean ± SD.
† n = 19.
‡ n = 21.
BMI, body mass index; CPK, creatine phosphokinase;
NIV, noninvasive ventilation; PaCO2, partial pressure of
arterial carbon dioxide; VC, vital capacity.
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relationship was observed between reductions in VC and MEP
(r2 = 0.47, p < 0.001). In 9 patients (41%), however, despite a
reduction in MEP, VC remained in the normal range (>80%
predicted). The patients receiving ventilatory support (open
symbols) tended to have the most severely reduced % predicted
MEP values.
3.3. Mechanism of respiratory failure in LOPD
Respiratory failure did not develop in any patient during the
study, in accord with the stability of lung function demonstrated
above; therefore, the mechanism for development of respiratory
failure was evaluated from cross-sectional data, which
integrates assessment of respiratory control and dead space to
traditional clinical assessment of VC and MIP.
The relationship of arterial PCO2 (PaCO2) to VC and MIP
are shown in Fig. 4. Daytime hypercapnia (PaCO2 > 50 mmHg)
was related to a reduction in both VC and MIP. The data were
nonlinear, and hypercapnia was present only when VC and MIP
were below thresholds of 60% and 40% predicted, respectively.
In 2 patients, however, normal values for PaCO2 were noted
despite respiratory dysfunction below these thresholds, which
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Fig. 1. Evolution of VC and MIP in the study cohort. Longitudinal data available and shown for 18 of 22 patients. VC, vital capacity; MIP, maximum inspiratory
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likely reflects normalization of PaCO2 after initiation of
mechanical ventilatory support.
Fig. 5 illustrates the relationships of PaCO2 to respiratory
pattern and efficiency of CO2 clearance. Data are illustrated for
the 17 patients that successfully completed the assessments.
The top panel illustrates the relationship between PaCO2 and
VT. Variability of VT was noted across patients, ranging from
normal values >400–500 ml to values as low as ≈300 ml. A
reduction in VT was observed in 5 of the 6 patients with chronic
hypercapnia (PaCO2 > 50 mmHg) who required ventilatory
support (open circles). The bottom panel illustrates the
relationship between PaCO2 and the dead space fraction (VD/
VT). The VD/VT varied from normal values (<0.3) to markedly
elevated values of >0.40. Normal PaCO2 values of
35–40 mmHg were associated with normal VD/VT, while
chronic hypercapnia was associated with elevated VD/VT,
compatible with reduced efficiency of CO2 clearance. The data
are consistent with increased VD/VT due to falling VT.
The relationship of PaCO2 to ventilatory CO2 responsiveness
is shown in Fig. 6. Data are illustrated for the 20 patients that
completed the assessment. The ventilatory response to CO2
varied from normal in 8 patients (≥1.5 l/min/mmHg) to
significant reductions in 10 patients (≤0.7 l/min/mmHg). The
presence of hypercapnia and/or ventilatory support was
associated with a reduced ventilatory responsiveness to CO2.
Two patients demonstrated reduced CO2 responsiveness despite
normal PaCO2 below 40 mmHg.
4. Discussion
We evaluated the relationships between measures of
pulmonary function, respiratory muscle strength, gas exchange,
and respiratory control to identify determinants of disease
progression from respiratory dysfunction to failure in LOPD
patients. Since the study was designed to evaluate the natural
history of Pompe disease, data were analyzed from patients that
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were studied prior to approval of enzyme replacement therapy.
Our results demonstrate that reduced CO2 clearance efficiency
as well as reduced ventilatory responsiveness may underlie the
development of chronic daytime hypercapnia (ie, respiratory
failure). The data also support the use of direct measures of
respiratory muscle strength (eg, MIP) in combination with
indirect measures (eg, VC) for the timely diagnosis of
respiratory insufficiency in LOPD.
4.1. Identification of respiratory insufficiency
Prior studies show that respiratory insufficiency in
neuromuscular diseases including LOPD manifests as a
restrictive pattern on spirometry testing, primarily a decrease in
VC [3,23–26]. A fall in VC in the supine position (compared
with upright) is used as an indirect indicator of the role of
+ Ventilatory support
-  Ventilatory support
0 20 40 60 80 100 120
VC (% predicted)
0 20 40 60 80 100 120
MIP (% predicted)
80
70
60
50
40
30
20
A
rt
er
ia
l P
C
O
2 
(m
m
H
g
)
80
70
60
50
40
30
20
A
rt
er
ia
l P
C
O
2 
(m
m
H
g
)
Fig. 4. Relationship of arterial PCO2 to VC (left) and MIP (right). MIP,
maximum inspiratory pressure; PCO2, partial pressure of carbon dioxide.
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diaphragm weakness [26–31]. Weakness of inspiratory as well
as expiratory muscles has been confirmed with direct
measurement of respiratory muscle output (MIP and MEP)
[3,32]. Abnormal structure of the inspiratory and expiratory
muscles was recently illustrated in patients with LOPD using
computed tomography and magnetic resonance imaging
techniques [5,33].
The present study confirms and augments these observations
by demonstrating a nonlinear relationship between MIP and
VC. A plateau of VC was noted in patients with mild respiratory
dysfunction (ie, normal to mild reduction in MIP). This finding
has implications for diagnosis of mild respiratory muscle
weakness, as reduction in MIP likely precedes the fall of VC
into the abnormal range. A role for the measurement of VC in
the supine position, as an early marker of respiratory
dysfunction, was not addressed in this study, but was
demonstrated by van der Beek and colleagues [3].
The present study extends previous reports by demonstrating
that the volume generated for any given degree of inspiratory
muscle function is lower than predicted, which implies
alteration in mechanical properties of either the lung or chest
wall. For example, lung compliance may fall in LOPD due to
development of microatelectasis, a common finding in patients
with neuromuscular disease [34], or due to remodeling in lung
parenchyma. Although the latter possibility seems unlikely,
there are limited pulmonary histologic data in Pompe disease,
and parenchymal changes have been suggested in other
neuromuscular disorders [34]. Also, recent postmortem studies
in LOPD patients demonstrated pulmonary fibrosis, veno-
occlusive disease, and glycogen deposition in vascular smooth
muscle [35,36]. Alternatively, chest wall mechanics can be
altered by the presence of kyphoscoliosis, a frequent finding in
patients with trunk weakness [37]. In either case, the degree of
respiratory restriction in an individual may not be reliably
predicted by measurement of respiratory muscle strength alone;
this discrepancy would be further enhanced in a given patient if
additional respiratory disease was present.
4.2. Longitudinal assessment of lung function
Few studies have published longitudinal data with respect to
the natural history of respiratory function in untreated
individual patients with LOPD. Although progressive decline
would be expected in patients with a progressive neuromuscular
disease, data obtained in the control group in the phase 3 trial of
alglucosidase alfa suggest that lung function may have been
stable in individual subjects. Specifically, while the mean
change in VC was a 2.2% decline over 1.5 years, the confidence
interval extended close to zero, consistent with stability of lung
function in some subjects. Data in individual patients published
by Pellegrini et al. [38] demonstrated stability or improvement
in lung function in selected patients over time periods ranging
up to 15 years. In accord with these findings, the present study
demonstrated that the evolution of lung function was highly
variable, with the majority of subjects demonstrating either
stability or improvement in lung function during a time period
ranging up to 2 years. Of note, evaluation of the subgroup that
demonstrated an increase in VC >5%, showed no evidence for
improved diaphragm strength since MIP and IC remained
stable. These data imply improvement in either expiratory
muscle function or improved technique of performing the
testing maneuver. The above considerations are particularly of
interest as new therapies for Pompe disease are being developed
and clinical trials are likely in the near future.
4.3. Development of respiratory failure
The present study adds to our understanding of the
mechanism of hypercapnia in patients with LOPD. Prior studies
have focused on the role for respiratory muscle weakness and
sleep-disordered breathing [6,39]. In general, hypercapnia
develops when VC falls below ≈40% predicted [7,15,16].
However, while it is tempting to attribute the hypercapnia to this
abnormality, hypercapnic patients in the present study
demonstrated variable ventilatory reserve as assessed by the
relationship between VC and the resting tidal volume. On
average, the measured VC in these patients was 885 ml greater
than their tidal volume and varied from low to high values
(range 387–1744 ml). When ventilatory reserve is low, a rapid
shallow breathing pattern would develop with consequent
hypercapnia. The observed increase in dead space fraction for
each breath (VD/VT) would further compromise alveolar
ventilation and contribute to the development of respiratory
failure. However, the reason for hypercapnia in patients with
larger ventilatory reserve is unclear; chest radiographs did not
reveal chest wall disease or diffuse parenchymal changes,
indicating that these patients should have been able generate a
larger tidal volume. We suggest therefore that development of
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hypercapnia in patients with large ventilatory reserve may
involve mechanisms related to the presence of sleep-disordered
breathing and blunted ventilatory responsiveness.
Prior studies in patients with neuromuscular disease have
indicated that nocturnal hypoventilation develops at VC levels
similar to those noted with onset of daytime hypercapnia (≈40%
predicted) [7,14,15,40,41]. This observation suggests that the
acute hypercapnia that develops during sleep hypoventilation
episodes is linked to the maintenance of chronic daytime
hypercapnia. However, those studies do not address the
mechanisms that underlie the perpetuation of the hypercapnic
state throughout wakefulness when ventilation would
presumably return to the baseline level. Maintenance of blood
PCO2 in the normal range in the presence of episodic
hypoventilation requires a compensatory increase in ventilation
upon awakening [42,43]. In fact, in amyotrophic lateral
sclerosis the earliest manifestation of respiratory failure has
been documented as a normal PCO2 during wakefulness but
with an elevated serum bicarbonate concentration. In these
patients, CO2 and bicarbonate retention likely occur during
sleep, but there is adequate ventilatory compensation during
wakefulness [23]. In patients with more severe limitation, the
ventilatory reserve may be insufficient to accommodate the
hyperventilation required to return daytime PCO2 to the normal
range. In addition, the observed reduction in ventilatory
responsiveness in hypercapnic patients would further impair
the compensatory hyperventilation despite the presence of
adequate ventilatory reserve.
The mechanism for impairment of ventilatory control in
LOPD is of interest. Reduction in respiratory muscle strength
could explain blunting of respiratory responsiveness. In accord
with this consideration, the subjects with the greatest degree of
respiratory muscle weakness in the present study all
demonstrated reduced ventilatory responsiveness. Of particular
interest was demonstration of reduced ventilatory response in 2
additional patients that were not receiving ventilatory support
and who demonstrated normal arterial PCO2 values. Since these
individuals had either normal or near normal MIP, MEP, and
VC, respiratory muscle weakness was not the likely mechanism
for the observed reduction in ventilatory response. One
potential explanation may relate to accumulation of glycogen in
the spinal cord and brain tissue, which has been shown both in
patients with Pompe disease [44] and in a mouse model of
Pompe disease [45]. Specific functional assessment of these
mice demonstrated blunting of CO2 response that was not
attributable to diaphragm weakness and, therefore, was
suggestive of a central control abnormality. The present study
design could not distinguish a contribution of central control
abnormalities to the development of chronic respiratory failure
in LOPD. This mechanism may be relevant to an ongoing
clinical trial investigating the utility of diaphragmatic pacing in
LOPD [46].
In summary, the present study confirms prior observations
that the development of daytime hypercapnia in patients with
LOPD is tightly linked to both the degree of respiratory muscle
weakness and the resulting severity of pulmonary dysfunction.
Our results extend prior observations by demonstrating that
hypercapnia is also linked to inefficiency in CO2 clearance from
either reduced ventilatory reserve or the inability to compensate
for sleep-disordered breathing. Finally, an abnormality in
respiratory control, identified in a subset of patients, may
contribute to the development of chronic daytime hypercapnia.
These observations suggest that development of hypercapnia
may not be related to the muscle dysfunction per se, but may
reflect inadequate compensatory hyperventilation in response
to stressors of respiratory function (eg, exercise, sleep-
disordered breathing, and infection).
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